ZA200407187B - Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. - Google Patents

Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. Download PDF

Info

Publication number: ZA200407187B
Authority: ZA; South Africa
Prior art keywords: group; alkoxy; alkyl; substituted; halogen atom
Prior art date: 2002-08-09

Application number

ZA200407187A

Other languages

English (en)

Inventor

Masakuzu Sato

Hiroyuki Kakinuma

Hajime Asanuma

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-09

Filing date

2004-09-08

Publication date

2006-02-22

2004-09-08 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2006-02-22 Publication of ZA200407187B publication Critical patent/ZA200407187B/en

Links

125000003118 aryl group Chemical group 0.000 title claims description 16
206010012601 diabetes mellitus Diseases 0.000 title claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 42
125000005843 halogen group Chemical group 0.000 claims description 38
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
125000003545 alkoxy group Chemical group 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 24
125000002252 acyl group Chemical group 0.000 claims description 22
125000001424 substituent group Chemical group 0.000 claims description 21
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
125000003710 aryl alkyl group Chemical group 0.000 claims description 14
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
125000003277 amino group Chemical group 0.000 claims description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
125000004423 acyloxy group Chemical group 0.000 claims description 7
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 7
125000000000 cycloalkoxy group Chemical group 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000004442 acylamino group Chemical group 0.000 claims description 6
125000003282 alkyl amino group Chemical group 0.000 claims description 6
125000004414 alkyl thio group Chemical group 0.000 claims description 6
125000001691 aryl alkyl amino group Chemical group 0.000 claims description 6
125000004104 aryloxy group Chemical group 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
125000000542 sulfonic acid group Chemical group 0.000 claims description 6
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 5
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
229940124597 therapeutic agent Drugs 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
108091006299 SLC2A2 Proteins 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
229940123208 Biguanide Drugs 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
239000003316 glycosidase inhibitor Substances 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
239000000556 agonist Substances 0.000 claims 4
125000004429 atom Chemical group 0.000 claims 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
229920000180 alkyd Polymers 0.000 claims 2
150000004677 hydrates Chemical class 0.000 claims 2
229910052739 hydrogen Inorganic materials 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
239000003112 inhibitor Substances 0.000 claims 2
229940123324 Acyltransferase inhibitor Drugs 0.000 claims 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
102000004190 Enzymes Human genes 0.000 claims 1
229940122069 Glycosidase inhibitor Drugs 0.000 claims 1
229940122355 Insulin sensitizer Drugs 0.000 claims 1
102000000853 LDL receptors Human genes 0.000 claims 1
108010001831 LDL receptors Proteins 0.000 claims 1
101150014691 PPARA gene Proteins 0.000 claims 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
239000002404 acyltransferase inhibitor Substances 0.000 claims 1
230000001539 anorectic effect Effects 0.000 claims 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
206010061428 decreased appetite Diseases 0.000 claims 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
229940125753 fibrate Drugs 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
230000003228 microsomal effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
-1 or a : 20 CC Chemical group 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
229940121649 protein inhibitor Drugs 0.000 claims 1
239000012268 protein inhibitor Substances 0.000 claims 1
230000000580 secretagogue effect Effects 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 description 4
230000030558 renal glucose absorption Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000000034 method Methods 0.000 description 3
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
IJJLRUSZMLMXCN-SLPGGIOYSA-N (2r,3r,4s,5r)-2,3,4,6-tetrahydroxy-5-sulfanylhexanal Chemical class OC[C@@H](S)[C@@H](O)[C@H](O)[C@@H](O)C=O IJJLRUSZMLMXCN-SLPGGIOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 1
235000019139 phlorizin Nutrition 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

ZA200407187A 2002-08-09 2004-09-08 Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. ZA200407187B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002233015		2002-08-09
JP2003097839		2003-04-01
PCT/JP2003/010159 WO2004014930A1 (ja)	2002-08-09	2003-08-08	選択的なアリール５−チオ−β−Ｄ−アルドヘキソピラノシドの製造法

Publications (1)

Publication Number	Publication Date
ZA200407187B true ZA200407187B (en)	2006-02-22

Family

ID=31719867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200407187A ZA200407187B (en)	2002-08-09	2004-09-08	Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me.

Country Status (19)

Country	Link
US (2)	US7414072B2 (ko)
EP (2)	EP1528066A4 (ko)
JP (2)	JPWO2004014930A1 (ko)
KR (2)	KR20050056194A (ko)
CN (2)	CN100341885C (ko)
AU (2)	AU2003254903B9 (ko)
BR (1)	BR0310006A (ko)
CA (2)	CA2493491A1 (ko)
HK (2)	HK1077582A1 (ko)
HR (1)	HRP20040814A2 (ko)
MX (2)	MXPA04009265A (ko)
NO (2)	NO20043733L (ko)
NZ (1)	NZ535229A (ko)
PL (2)	PL372865A1 (ko)
RU (1)	RU2322449C2 (ko)
TW (2)	TW200409778A (ko)
UA (1)	UA77300C2 (ko)
WO (2)	WO2004014931A1 (ko)
ZA (1)	ZA200407187B (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
JP4477504B2 (ja) *	2002-11-13	2010-06-09	大正製薬株式会社	鎮痒剤
EP1609799A4 (en) *	2003-04-01	2008-10-29	Taisho Pharmaceutical Co Ltd	HETEROARYL-5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND AGENTS AGAINST DIABETES THEREOF
AR045173A1 (es)	2003-08-01	2005-10-19	Tanabe Seiyaku Co	Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
TW200606129A (en)	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
ZA200700755B (en) *	2004-07-26	2009-05-27	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
TW200637839A (en) *	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MY147375A (en)	2005-01-31	2012-11-30	Mitsubishi Tanabe Pharma Corp	Indole derivatives
JP5073948B2 (ja) *	2005-01-31	2012-11-14	田辺三菱製薬株式会社	医薬組成物
JP2009167104A (ja) *	2006-05-02	2009-07-30	Taisho Pharmaceutical Co Ltd	フェニル５−チオグリコシド化合物
EP1854806A1 (en) *	2006-05-02	2007-11-14	MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Thioglycosides as pharmaceutically active agents
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
JP5230613B2 (ja) *	2006-05-23	2013-07-10	テラコス・インコーポレイテッド	グルコース輸送体阻害剤およびその使用方法
US8115017B2 (en) *	2006-06-29	2012-02-14	Taisho Pharmaceutical Co., Ltd	C-phenyl 1-thioglucitol compound
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
FR2906247B1 (fr) *	2006-09-27	2008-12-26	Fournier S A Sa Lab	Nouveaux derives de 5-thioxylopyranose
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
EP2072522A4 (en) *	2006-10-13	2010-01-06	Chugai Pharmaceutical Co Ltd	THIOGLUCOSE SPIROCETAL DERIVATIVE AND USE THEREOF AS A THERAPEUTIC AGENT FOR DIABETES
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7666845B2 (en)	2006-12-04	2010-02-23	Janssen Pharmaceutica N.V.	Compounds having inhibitory activity against sodium-dependent glucose transporter
CN101611023A (zh)	2006-12-14	2009-12-23	大正制药株式会社	1－苯基1－硫代－d－山梨醇衍生物
US7795228B2 (en) *	2006-12-28	2010-09-14	Theracos, Inc.	Spiroheterocyclic glycosides and methods of use
US7846945B2 (en) *	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
US20080064701A1 (en) *	2007-04-24	2008-03-13	Ramesh Sesha	Anti-diabetic combinations
US20070172525A1 (en) *	2007-03-15	2007-07-26	Ramesh Sesha	Anti-diabetic combinations
AU2008232419B2 (en) *	2007-04-02	2013-06-20	Theracos, Inc.	Benzylic glycoside derivatives and methods of use
KR101663324B1 (ko)	2007-07-26	2016-10-06	렉시컨 파마슈티컬스 인코퍼레이티드	나트륨 글루코스 공-전달체 2 억제제의 제조에 유용한 방법 및 화합물
PL2187742T3 (pl) *	2007-08-23	2018-06-29	Theracos Sub, Llc	Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy
HUE035130T2 (en)	2007-09-10	2018-05-02	Janssen Pharmaceutica Nv	A method for preparing compounds useful as SGLT inhibitors
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) *	2008-03-14	2013-10-08	Iycus, Llc	Anti-diabetic combinations
TWI523652B (zh)	2008-07-15	2016-03-01	泰瑞克公司	氘化苄基苯衍生物及使用方法
AR073118A1 (es) *	2008-08-22	2010-10-13	Theracos Inc	Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo.
BRPI0918841B8 (pt) *	2008-08-28	2021-05-25	Pfizer	derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
JP5658751B2 (ja)	2009-07-10	2015-01-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	１−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
DK2488515T3 (en)	2009-10-14	2017-02-27	Janssen Pharmaceutica Nv	PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
SI2496583T1 (sl)	2009-11-02	2015-02-27	Pfizer Inc.	Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
MX339570B (es)	2010-05-11	2016-05-31	Janssen Pharmaceutica Nv	Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
WO2011153712A1 (en)	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
SI2697218T1 (sl)	2011-04-13	2016-07-29	Janssen Pharmaceutica Nv	Postopek za pripravo spojin, koristnih kot zaviralci sglt2
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
TWI637963B (zh)	2012-03-28	2018-10-11	富士軟片股份有限公司	１－（２－脫氧－２－氟－４－硫－β－Ｄ－***呋喃糖基）胞嘧啶之鹽
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
PL2883866T3 (pl)	2012-08-13	2019-07-31	Fujifilm Corporation	Produkt pośredni do syntezy 1-(2-deoksy-2-fluoro-4-tio-beta-d-arabinofuranosylo)cytozyny, produkt pośredni do syntezy tionukleozydu i sposoby otrzymywania tych produktów pośrednich
US10202356B2 (en)	2013-03-14	2019-02-12	Tolero Pharmaceuticals, Inc.	JAK2 and ALK2 inhibitors and methods for their use
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt)	2013-04-05	2019-02-19	Boehringer Ingelheim Int	Utilizações terapêuticas de empagliflozina
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh)	2013-04-18	2021-07-30	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
CN105611920B (zh)	2013-10-12	2021-07-16	泰拉科斯萨普有限责任公司	羟基-二苯甲烷衍生物的制备
JP6175553B2 (ja)	2014-02-18	2017-08-09	富士フイルム株式会社	チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6204223B2 (ja)	2014-02-19	2017-09-27	富士フイルム株式会社	チオピラノース化合物等の製造方法
TWI678373B (zh)	2014-10-31	2019-12-01	日商富士軟片股份有限公司	硫代核苷衍生物或其鹽及醫藥組合物
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
MX2019002430A (es)	2016-08-31	2019-07-04	Fujifilm Corp	Agente antitumoral, mejorador del efecto antitumoral, y kit antitumoral.
CA3089728C (en)	2018-01-29	2023-01-10	Fujifilm Corporation	Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0850948T3 (da)	1996-12-26	2002-07-29	Tanabe Seiyaku Co	Propiophenonderivater og fremgangsmåde til fremstilling deraf
JP3055135B2 (ja) *	1996-12-26	2000-06-26	田辺製薬株式会社	プロピオフェノン誘導体及びその製法
PL203124B1 (pl) *	1999-08-31	2009-08-31	Kissei Pharmaceutical	Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna je zawierająca i związki pośrednie
FR2801055B1 (fr) *	1999-11-17	2002-02-08	Fournier Ind & Sante	Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
BR0109323A (pt) *	2000-03-17	2002-12-24	Kissei Pharmaceutical	Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
ES2214432T3 (es)	2000-05-20	2004-09-16	Tesa Ag	Utilizacion de un soporte de papel de elevada densidad como tira soporte en un material de revestimiento para una cinta adhesiva.
SI1329456T1 (sl) *	2000-09-29	2006-12-31	Kissei Pharmaceutical	Glukopiranoziloksibenzilbenzenski derivati in zdravilni sestavki, ki vsebujejo te spojine
EP1338603B1 (en) *	2000-11-02	2010-01-20	Ajinomoto Co., Inc.	Novel pyrazole derivatives and diabetes remedies containing the same
ES2326158T3 (es)	2000-12-28	2009-10-02	Kissei Pharmaceutical Co., Ltd.	Derivados de glucopiranosiloxipirazol y su utilizacion como medicamentos.
JP4399254B2 (ja)	2001-06-20	2010-01-13	キッセイ薬品工業株式会社	含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
US7439232B2 (en)	2003-04-01	2008-10-21	Taisho Pharmaceutical Co., Ltd.	Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
EP1609799A4 (en) *	2003-04-01	2008-10-29	Taisho Pharmaceutical Co Ltd	HETEROARYL-5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND AGENTS AGAINST DIABETES THEREOF

2003
- 2003-08-08 BR BR0310006-5A patent/BR0310006A/pt not_active IP Right Cessation
- 2003-08-08 EP EP03784623A patent/EP1528066A4/en not_active Withdrawn
- 2003-08-08 JP JP2004527382A patent/JPWO2004014930A1/ja not_active Ceased
- 2003-08-08 CN CNB038191423A patent/CN100341885C/zh not_active Expired - Fee Related
- 2003-08-08 CA CA002493491A patent/CA2493491A1/en not_active Abandoned
- 2003-08-08 US US10/518,788 patent/US7414072B2/en not_active Expired - Fee Related
- 2003-08-08 NZ NZ535229A patent/NZ535229A/en unknown
- 2003-08-08 WO PCT/JP2003/010160 patent/WO2004014931A1/ja active IP Right Grant
- 2003-08-08 RU RU2004135914/04A patent/RU2322449C2/ru not_active IP Right Cessation
- 2003-08-08 PL PL03372865A patent/PL372865A1/xx not_active Application Discontinuation
- 2003-08-08 CN CNB038056402A patent/CN1312165C/zh not_active Expired - Fee Related
- 2003-08-08 MX MXPA04009265A patent/MXPA04009265A/es active IP Right Grant
- 2003-08-08 UA UA20041210074A patent/UA77300C2/uk unknown
- 2003-08-08 KR KR1020057002280A patent/KR20050056194A/ko not_active Application Discontinuation
- 2003-08-08 AU AU2003254903A patent/AU2003254903B9/en not_active Ceased
- 2003-08-08 KR KR1020047014192A patent/KR100588457B1/ko not_active IP Right Cessation
- 2003-08-08 EP EP03784622A patent/EP1541578A1/en not_active Withdrawn
- 2003-08-08 AU AU2003254904A patent/AU2003254904A1/en not_active Abandoned
- 2003-08-08 PL PL03375298A patent/PL375298A1/xx not_active Application Discontinuation
- 2003-08-08 US US10/521,809 patent/US7250522B2/en not_active Expired - Fee Related
- 2003-08-08 WO PCT/JP2003/010159 patent/WO2004014930A1/ja active Application Filing
- 2003-08-08 TW TW092121895A patent/TW200409778A/zh unknown
- 2003-08-08 JP JP2004527383A patent/JP3813160B2/ja not_active Expired - Fee Related
- 2003-08-08 TW TW092121886A patent/TWI274055B/zh not_active IP Right Cessation
- 2003-08-08 CA CA002478889A patent/CA2478889A1/en not_active Abandoned
- 2003-08-08 MX MXPA05000725A patent/MXPA05000725A/es active IP Right Grant
2004
- 2004-09-07 NO NO20043733A patent/NO20043733L/no not_active Application Discontinuation
- 2004-09-08 HR HR20040814A patent/HRP20040814A2/hr not_active Application Discontinuation
- 2004-09-08 ZA ZA200407187A patent/ZA200407187B/en unknown
2005
- 2005-02-07 NO NO20050650A patent/NO20050650L/no not_active Application Discontinuation
- 2005-10-27 HK HK05109578A patent/HK1077582A1/xx not_active IP Right Cessation
- 2005-12-17 HK HK05111661A patent/HK1079532A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
US20050209309A1 (en)	2005-09-22
EP1528066A4 (en)	2007-05-02
KR20050018642A (ko)	2005-02-23
TWI274055B (en)	2007-02-21
WO2004014931A1 (ja)	2004-02-19
PL372865A1 (en)	2005-08-08
TW200406396A (en)	2004-05-01
CN1675233A (zh)	2005-09-28
AU2003254903B2 (en)	2008-07-31
NZ535229A (en)	2006-05-26
US7250522B2 (en)	2007-07-31
CN100341885C (zh)	2007-10-10
EP1528066A1 (en)	2005-05-04
MXPA04009265A (es)	2005-01-25
HRP20040814A2 (en)	2005-06-30
EP1541578A1 (en)	2005-06-15
CN1639180A (zh)	2005-07-13
US7414072B2 (en)	2008-08-19
AU2003254904A1 (en)	2004-02-25
KR100588457B1 (ko)	2006-06-12
NO20043733L (no)	2004-10-20
CA2478889A1 (en)	2004-02-19
JPWO2004014931A1 (ja)	2005-12-02
RU2322449C2 (ru)	2008-04-20
RU2004135914A (ru)	2005-05-10
MXPA05000725A (es)	2005-04-08
BR0310006A (pt)	2005-02-15
US20050256317A1 (en)	2005-11-17
KR20050056194A (ko)	2005-06-14
UA77300C2 (en)	2006-11-15
JP3813160B2 (ja)	2006-08-23
WO2004014930A1 (ja)	2004-02-19
HK1079532A1 (en)	2006-04-07
PL375298A1 (en)	2005-11-28
NO20050650L (no)	2005-03-04
TW200409778A (en)	2004-06-16
AU2003254903A1 (en)	2004-02-25
CN1312165C (zh)	2007-04-25
HK1077582A1 (en)	2006-02-17
JPWO2004014930A1 (ja)	2005-12-02
AU2003254903B9 (en)	2008-08-21
CA2493491A1 (en)	2004-02-19

Publication	Publication Date	Title
ZA200407187B (en)	2006-02-22	Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me.
Hagmann et al.	1986	Identification of the major endogenous leukotriene metabolite in the bile of rats as N-acetyl leukotrience E4
CN1133434C (zh)	2004-01-07	作为治疗剂的环戊烷庚烷(烯)酸、2-杂芳基链烯基衍生物
US5902610A (en)	1999-05-11	Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate
TWI326687B (en)	2010-07-01	Amide prodrug of gemcitabine, compositions and use thereof
CA1302275C (en)	1992-06-02	Enzyme inhibitor
US20110077212A1 (en)	2011-03-31	Therapeutic uses of sglt2 inhibitors
Rainsford	2015	Pharmacology and toxicology of ibuprofen
EP0259990A1 (en)	1988-03-16	Rapid acting combination of sodium sulindac and a base
CS247191B2 (en)	1986-12-18	Method of acetylerythromycinstearate preparation
Saari et al.	1984	3-Hydroxy-. alpha.-methyltyrosine progenitors, synthesis and evaluation of some (2-oxo-1, 3-dioxol-4-yl) methyl esters
AU2007341218B2 (en)	2010-09-09	Isosorbide mononitrate derivatives for the treatment of intestinal disorders
HU183346B (en)	1984-04-28	Process for preparing new 3,4,5-trihydroxy-piperidine derivatives
BG64458B1 (bg)	2005-03-31	Използване на цинков хиалуронат срещу пептична язва
EP1857442A3 (en)	2008-02-06	Novel antimycobacterial compounds
US5728402A (en)	1998-03-17	Controlled release formulation of captopril or a prodrug of captopril
EP1723956A1 (en)	2006-11-22	Preventive or therapeutic agents for severe diabetic retinopathy
FI68970B (fi)	1985-08-30	Foerfarande foer framstaellning av en ny medicinskt anvaendbarhemin-foerening
US20020128235A1 (en)	2002-09-12	Prevention and/or treatment of diabetes mellitus by pharmacologically inhibiting pancreatic beta-cell O-linked protein glycosylation and/or pancreatic beta-cell p135 O-glycosylation
KR102401604B1 (ko)	2022-05-24	데스메틸클로자핀의 새로운 용도
Stenlake	1979	Biodegradable neuromuscular blocking agents
JP2766303B2 (ja)	1998-06-18	グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法
US4125610A (en)	1978-11-14	Antibacterial compositions
CA1271191A (en)	1990-07-03	Alpha-tocopherol (halo)uridine phosphoric acid diester, salts thereof, and methods for producing the same
WO2002055661A2 (en)	2002-07-18	Fatty acid synthase inhibitors